Mazdutide
Mazdutide is a weekly weight-loss injection approved in China in 2025. It is not FDA-approved and is not legally available in the United States.
- Legal lane: not approved in the US. Approved in China for weight management and type 2 diabetes.
- Evidence grade: B
- Form: weekly injection under the skin
- US status: in earlier-stage trials; no FDA filing yet
What it is
Mazdutide activates two hormone receptors, GLP-1 and glucagon. It was created at Eli Lilly and is developed in China by Innovent Biologics. Lilly holds the rights elsewhere.
What the evidence shows
The evidence comes from Phase 3 trials in Chinese adults.
- GLORY-1 (published in the New England Journal of Medicine, 2025): about 12% average weight loss on 4 mg and about 15% on 6 mg at 48 weeks.
- GLORY-2 (published in JAMA, 2026): on 9 mg, average weight loss of roughly 17% to 19% at 60 weeks, depending on how the analysis handles people who stopped treatment.
These are solid, published trials, but in one population. Results in US patients are not yet known, which is why the grade is B.
Dosing used in the trials
There is no US dose. In GLORY-2, treatment started at 3 mg once a week and rose by 3 mg every four weeks, reaching the 9 mg maintenance dose at week 8. GLORY-1 tested 4 mg and 6 mg.
Legal status
China approved mazdutide for chronic weight management in June 2025 and for type 2 diabetes in September 2025. A Chinese approval does not make it legal to sell in the US. Products sold online as mazdutide are unapproved here, and the FDA named it in a 2026 warning letter to a research-peptide seller.